However, in agreement with our tumor model data (Figure 1E), we observed that the frequency of Granzyme B+ OT-I was considerably lower in both the α4-1BB and isotype-control treated groups treated with high-dose EZH2i (Figure 2C). Here, GZMB is linked to neoplasm.